Hans-Jürgen Stellbrink

Statistics

Publications

Citations

3.2K

H-Index

Active since

1995

Affiliations

Infektionsmedizinisches Centrum Hamburg(Current)

Universität Hamburg

University Medical Center Hamburg-Eppendorf

Chelsea and Westminster Hospital

Hospital Universitari Germans Trias i Pujol

Hans-Jürgen Stellbrink is an author at Infektionsmedizinisches Centrum Hamburg specializing in antiretroviral therapy, antiviral therapy, and pharmacotherapy.

Publications per year

1995–2019

Publications

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 750 citations · Full text

Public Health, Pharmacotherapy, Clinical Epidemiology +15

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Adriano Lazzarin, Bonaventura Clotet, David A. Cooper et al. · New England Journal of Medicine · 2003 · 653 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 504 citations

Medicine, Pharmacology, Pharmacotherapy +14

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 395 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Dolutegravir in antiretroviral-naive adults with HIV-1

Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin et al. · AIDS · 2013 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 14